Bioventus (BVS) Competitors

Bioventus (NYSE:BVS) and Axonics (NASDAQ:AXNX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.

Do analysts recommend BVS or AXNX?

Bioventus presently has a consensus target price of $13.00, indicating a potential upside of 13.94%. Axonics has a consensus target price of $71.00, indicating a potential upside of 0.03%. Given Bioventus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bioventus is more favorable than Axonics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Axonics	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the MarketBeat Community favor BVS or AXNX?

Axonics received 144 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 66.41% of users gave Axonics an outperform vote while only 63.83% of users gave Bioventus an outperform vote.

Company	Underperform	Outperform
Bioventus	Outperform Votes 30 63.83%	Underperform Votes 17 36.17%
Axonics	Outperform Votes 174 66.41%	Underperform Votes 88 33.59%

Does the media refer more to BVS or AXNX?

In the previous week, Axonics had 6 more articles in the media than Bioventus. MarketBeat recorded 7 mentions for Axonics and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.18 beat Axonics' score of 0.91 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axonics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in BVS or AXNX?

62.9% of Bioventus shares are held by institutional investors. Comparatively, 99.5% of Axonics shares are held by institutional investors. 32.9% of Bioventus shares are held by company insiders. Comparatively, 1.9% of Axonics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more volatility and risk, BVS or AXNX?

Bioventus has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Axonics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Is BVS or AXNX more profitable?

Axonics has a net margin of -1.31% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat Axonics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
Axonics	-1.31%	0.36%	0.31%

Which has better earnings and valuation, BVS or AXNX?

Axonics has lower revenue, but higher earnings than Bioventus. Axonics is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$512.34M	1.81	-$156.23M	-$0.61	-18.70
Axonics	$366.38M	9.90	-$6.09M	-$0.12	-591.45

Summary

Bioventus beats Axonics on 10 of the 18 factors compared between the two stocks.